Neurology

Airdoc Technology (02251.HK) achieved remarkable success in 2023, accelerating its commercialization in an unparalleled way  

Retrieved on: 
星期三, 四月 10, 2024
Consensus, Glaucoma, Conditional sentence, University, Finance, RMB, Risk, Approximation error, Patient, Artificial intelligence, Medical device, National Health Commission, Optometry, Endocrinology, Dementia, Certification, Hyperthyroidism, Ageing, Capital Medical University, Software, MICCAI, Hypertensive retinopathy, Beijing Tongren Hospital, Neurology, Acceleration, Intelligence, Paratriathlon, Hospital, Research, Near-sightedness, Amblyopia, AI, MDR, Strabismus, Skin, AMD, Ranibizumab, Diagnosis, Peking University, Growth, Cardiology, Physical examination, News, Cataract, Diabetic retinopathy, Ophthalmology

In 2023, Airdoc Technology significantly accelerated its commercialization，while most of its peers were still in the experimental stage or early stages of commercialization.

Key Points: 
  • In 2023, Airdoc Technology significantly accelerated its commercialization，while most of its peers were still in the experimental stage or early stages of commercialization.
  • 2) health risk assessment solutions, covering 55 types of lesions, providing chronic disease management and health assessments for healthcare industry.
  • Airdoc Technology practices the use of AI technology to assist in the prevention and control of myopia among teenagers and the development of eye health.
  • In July 2023, Airdoc Technology participated in the formulation of the "Expert Consensus on Assessing the Risk of Cardiovascular Diseases Using Artificial Intelligence Technology Based on Fundus Images."

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team

Retrieved on: 
星期二, 四月 9, 2024
College, Neurology, Neoplasm, Brain, M.B.A, Utrecht University, Oncology, Neuro, Central nervous system, Novartis, CNS, GBM, Biostatistics, Committee, Biology, Breast, University, Neurosurgery, PSTV, Cancer, Plus, Science park, Doctor of Philosophy, Glioblastoma, Therapy, Texas A&M University, Drug development, Halozyme, Plus Therapeutics, Pharmaceutical industry

AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that Andrew Brenner, M.D., Ph.D. (Professor-Research, Departments of Medicine, Neurology, and Neurosurgery & S & B Kolitz/CTRC-Zachry Endowed Chair Neuro-Oncology Research, Mays Cancer Center at UT Health San Antonio) has formally joined the Company in a part-time capacity. Dr. Brenner will provide substantial input on the Company’s central nervous system cancer development programs while continuing to maintain his academic practice and laboratory. In addition, Barbara Blouw, Ph.D. joins the Company as Vice President, Clinical Affairs.

Key Points: 
  • Dr. Brenner will provide substantial input on the Company’s central nervous system cancer development programs while continuing to maintain his academic practice and laboratory.
  • In addition, Barbara Blouw, Ph.D. joins the Company as Vice President, Clinical Affairs.
  • Dr. Brenner’s academic work focuses on both clinical cancer management and the development of novel therapies to treat breast and central nervous system tumors.
  • Dr. Brenner has received numerous grants and investigational new drug approvals based on his translational research.

Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024

Retrieved on: 
星期二, 四月 9, 2024
Neurology, University college, Patient, McGill University Health Centre, Head, Doctor of Philosophy, MDCM, OPMD, Otorhinolaryngology, Natural history

To register, click here .

Key Points: 
  • To register, click here .
  • The event will feature two key opinion leaders who will discuss the clinical symptoms and the natural history of oculopharyngeal muscular dystrophy (OPMD), a rare genetic muscle disorder.
  • The key opinion leaders will also review the clinical and radiographic methods employed to evaluate disease progression and discuss the current treatment landscape for patients diagnosed with OPMD.
  • A live question and answer session will follow the formal presentations.

Sutter Health Announces Significant Investment in a New Advanced Multi-Specialty Neurosciences Care Complex in San Francisco’s Mission Neighborhood

Retrieved on: 
星期四, 四月 4, 2024
Neurology, Diagnosis, Brain, Cardiology, Partnership, Physician, Health, Patient, SAN, Stroke, Research, Aneurysm, Elective surgery, Sutter Health, General surgery, Forbes Norris, Neurosurgery, Investment, Pediatrics, Hospital, Endocrinology, Podiatry, Graduate medical education, Rehabilitation, Nursing

The new Mission Bernal Care Complex, built on the site of the former St. Luke’s Hospital, will serve as an advanced, multi-specialty center for comprehensive neurological and neurosurgical care.

Key Points: 
  • The new Mission Bernal Care Complex, built on the site of the former St. Luke’s Hospital, will serve as an advanced, multi-specialty center for comprehensive neurological and neurosurgical care.
  • Finally, Sutter will expand primary care and women’s care services on the Mission Bernal Campus at the Monteagle building ( 1580 Valencia St .).
  • "At Sutter Health, the commitment to expanding access to high-quality care is unstoppable,” said Ken McNeely, Sutter Health board chair.
  • “This investment underscores the organization's dedication to meeting the health care needs of Northern California communities, ensuring that patients receive exceptional care close to home.

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia

Retrieved on: 
星期三, 四月 3, 2024
Depression, Neurology, Schizophrenia, Patent, CFO, Opioid use disorder, OTCQB

The USPTO has issued U.S. Patent No.

Key Points: 
  • The USPTO has issued U.S. Patent No.
  • 11,793,801 entitled, “Treatment of Pain and Neurological Conditions”.
  • The patent is directed towards the use of a compound and composition and/or dosage form for treating pain, depression, and schizophrenia.
  • Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., and President, and Chairman of BioCorRx Pharmaceuticals Inc., commented, “The patented invention may offer a novel approach to reducing the severity of withdrawal symptoms for opioid use disorder compared to current standards of care."

Largest Gift in SWBC History Makes Significant Impact on Pediatric Patients Needing Surgical Care

Retrieved on: 
星期一, 四月 1, 2024
Neurology, Rotation, Patient, SAN, History, Acquisition, SWBC, Insurance, Surgeon, Movement, Credit union, Medical device

The da Vinci Xi will be used across a spectrum of minimally invasive surgical procedures and is optimized for multi-quadrant surgeries.

Key Points: 
  • The da Vinci Xi will be used across a spectrum of minimally invasive surgical procedures and is optimized for multi-quadrant surgeries.
  • The unit provides 360-degree rotation and can operate on the smallest of patients without big incisions.
  • This gift is SWBC’s most significant donation in its history and comes as the company celebrates its 48th year in business.
  • “The SWBC Foundation’s gift of the da Vinci Xi robot at CHRISTUS Children’s has transformed the surgical care of our patients,” said Ian Thompson, CHRISTUS Children’s Foundation president and chief development officer.

Nxera Pharma is the New Name for Sosei Group

Retrieved on: 
星期一, 四月 1, 2024
Health, Growth, Neurology, Science, Patient, DSM-IV codes, GI, Therapy, Medicine, Fine chemical

Chris Cargill, President & CEO of Nxera Pharma, commented: “Our name change from Sosei Group to Nxera Pharma marks a pivotal moment in our Company’s journey.

Key Points: 
  • Chris Cargill, President & CEO of Nxera Pharma, commented: “Our name change from Sosei Group to Nxera Pharma marks a pivotal moment in our Company’s journey.
  • It follows the significant growth and development of the business, which has been accelerated through several key strategic acquisitions in recent years, including Heptares Therapeutics in 2015 and the Idorsia Pharmaceuticals Japan and Korea businesses in 2023.
  • “The Company decided that now is the optimal time to unify the business under a new name and bold brand.
  • I am extremely proud of what we have achieved since then and truly excited about what we, as Nxera Pharma, can deliver in the future, to our patients, partners, employees and shareholders, as this vision becomes a reality.

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

Retrieved on: 
星期四, 三月 28, 2024
Neurology, Friends, AAN, Social media, Annual general meeting

CAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease at the Annual Academy of Neurology (AAN) 2024 Annual Meeting , taking place April 13-18, 2024 virtually and in Denver, Colorado.

Key Points: 
  • CAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease at the Annual Academy of Neurology (AAN) 2024 Annual Meeting , taking place April 13-18, 2024 virtually and in Denver, Colorado.
  • Presentation details are as follows:
    The AAN Annual Meeting is the largest gathering of neurologists and neuroscience professionals and offers top-tier education, the latest in scientific discoveries, and an abundance of opportunities to connect with friends and colleagues from around the globe.
  • For more information about Vaxxinity, Inc., visit https://vaxxinity.com/ and follow us on social media @vaxxinity.

Tevogen Bio Announces Series A-1 Preferred Stock Investment

Retrieved on: 
星期四, 三月 28, 2024
Neurology, Virology, MPH, Therapy, Medicine, Security (finance)

WARREN, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has entered into a securities purchase agreement with an existing investor pursuant to which the investor agreed to purchase shares of newly designated Series A-1 Preferred Stock of the Company in lieu of Series A Preferred Stock that the investor earlier agreed to purchase, for an aggregate purchase price of $6.0 million.

Key Points: 
  • WARREN, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has entered into a securities purchase agreement with an existing investor pursuant to which the investor agreed to purchase shares of newly designated Series A-1 Preferred Stock of the Company in lieu of Series A Preferred Stock that the investor earlier agreed to purchase, for an aggregate purchase price of $6.0 million.
  • The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.00 conversion price of the Series A Preferred Stock, into a total of 600,000 shares of the Company’s common stock at the election of the holder.
  • The Series A-1 Preferred Stock is subject to a call right providing the Company the right to call the stock if the volume weighted average price of the common stock for the 20 days prior to delivery of the call notice is greater than $5.00 per share and there is an effective resale registration statement on file covering the underlying common stock.
  • The Series A-1 Preferred Stock is non-voting, has no mandatory redemption, carries an annual 5% cumulative dividend, increasing by 2% each year, with a cap of 12% per year.

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

Retrieved on: 
星期二, 三月 26, 2024
Neurology, Hospital, Consultant, Webcast, Patient, PXE, Event, Therapy, Pharmaceutical industry

BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call and webcast on Monday, April 8, 2024 at 8:00 a.m. Eastern Time.

Key Points: 
  • - Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m.
  • During the conference call and webcast, the Company will discuss topline data from its ongoing Phase 1/2 trial of INZ-701 in adults with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE), and from all cohorts of its ongoing Phase 1/2 trial of INZ-701 in adults with ENPP1 Deficiency.
  • Alternatively, the conference call may be accessed by dialing:
    Participants should ask to join the Inozyme Pharma call.
  • For those unable to participate live, a replay will be available in the Investor Relations section of Inozyme’s website for a limited time following the event.